Search clinical trials for: SHR6390

Total 62 results

The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Healthy Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers

Healthy Adult Male Volunteers

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR6390 in Advanced Solid Tumor Patients

Neoplasm

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Atridia Pty Ltd.

Completed

A Trial of SHR6390 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer

Gastric Cancer

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer (DAP-Her-01)

Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of SHR6390 in Renal Insufficiency and Healthy Subjects

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer

ER+ / HER2- Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Beijing 302 Hospital

Not yet recruiting

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

HR+/HER2- Advanced Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

ER-Positive, HER2-Negative Breast Cancer

China
Harbin Medical University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

HCC | NSCLC | CRC
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Solid Tumor

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

Breast Cancer

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Metastatic Breast Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients

Hormone Refractory Prostate Cancer | Metastatic Prostate Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects

Castration-Resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Advanced Solid Tumor

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Henan Cancer Hospital

Active, not recruiting

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

Metastatic Breast Cancer

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Breast Cancer | Metastatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects

Healthy Subjects

China
Shengjing Hospital

Active, not recruiting

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Breast Cancer

China
Shire

Completed

Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma

Ocular Hypertension | Primary Open-angle Glaucoma (POAG)

United States
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Breast Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Solid Tumor

China
Ruijin Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.

Breast Cancer | HER2-positive Breast Cancer | ER-positive Breast Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Jinming Yu
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (INPHASE)

Metastatic Breast Cancer | HER2-positive Breast Cancer

China
Ruijin Hospital

Not yet recruiting

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Prostate Cancer | Hormone-Dependent Prostate Cancer

China, Czechia, Poland, Bulgaria
Fudan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Healthy Subjects

China

Search clinical trials for: SHR6390

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations